Estrogen Promotes Resistance to Bevacizumab in Murine Models of NSCLC-Reference-Cited by-同舟云学术

Estrogen Promotes Resistance to Bevacizumab in Murine Models of NSCLC

Published:2021-12 Issue:12 Volume:16 Page:2051-2064
ISSN:1556-0864
Container-title:Journal of Thoracic Oncology
language:en
Short-container-title:Journal of Thoracic Oncology

Author:

Patel Sonia A.,Herynk Matthew H.,Cascone Tina,Saigal Babita,Nilsson Monique B.,Tran Hai,Ramachandran Sumankalai,Diao Lixia,Wang Jing,Le Xiuning,Minna John,Wistuba Ignacio I.,Heymach John V.

Publisher

Elsevier BV

Subject

Pulmonary and Respiratory Medicine,Oncology

Reference58 articles.

1. Cancer statistics, 2020;Siegel;CA Cancer J Clin,2020

2. Annual Report to the Nation on the Status of Cancer, part I: national cancer statistics;Cronin;Cancer,2018

3. Women’s susceptibility to tobacco carcinogens and survival after diagnosis of lung cancer;Henschke;JAMA,2006

4. Lung cancer incidence in never smokers;Wakelee;J Clin Oncol,2007

5. Are female smokers at higher risk for lung cancer than male smokers? A case-control analysis by histologic type;Risch;Am J Epidemiol,1993

Cited by 13 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Triple-transformable dynamic surroundings for programmed transportation of bio-vulnerable mRNA payloads towards systemic treatment of intractable solid tumors;Biomaterials;2024-12

2. A new perspective on antiangiogenic antibody drug resistance: Biomarkers, mechanisms, and strategies in malignancies;Drug Development Research;2024-09

3. Increased risk of subsequent primary lung cancer among female hormone-related cancer patients: A meta-analysis based on over four million cases;Chinese Medical Journal;2024-07-08

4. Sex as a Biological Variable in Early-Phase Oncology Clinical Trials: Enhancing the Path to Personalised Medicine;Heliyon;2024-06

5. Efficacy and safety of neoadjuvant immunotherapy plus chemotherapy followed by adjuvant immunotherapy in resectable non-small cell lung cancer: a meta-analysis of phase 3 clinical trials;Frontiers in Immunology;2024-04-05